Navigation Links
Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
Date:9/19/2013

MOSCOW, Sept. 19, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.

With recent advancements in production contract business development, as well as interest from several strategic partners, Rafarma will engage the services of a PCAOB registered audit firm. The Company also plans to streamline its corporate structure which will greatly lower administrative costs.

"This is the next step in Rafarma's maturity in the public markets," stated CEO Dave Anderson. "We're excited at the opportunity to upgrade our listing in the U.S and abroad."

About Rafarma Pharmaceuticals, Inc.

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of the nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

For more information on Rafarma Pharmaceuticals, visit: http://rafarma.com

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo

 


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc. (RAFA)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
2. Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
3. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
4. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
5. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
6. Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
8. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
9. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
10. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
11. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... N.Y. , Feb. 11, 2016  Governor Andrew ... that will create 1,400 jobs throughout Western ... a partnership with the SUNY Polytechnic Institute, includes a ... Conventus Building in Buffalo , as ... foot manufacturing facility in Dunkirk . ...
(Date:2/11/2016)...  NOIT™ Research LLC, a private, leading-edge autism research ... to assist needy families in obtaining one of its ... February 10, 2016 and March 31, 2016, the company ... NOIT is an auditory stimulus that plays a key ... Beth Shier , NOIT Research director. ...
(Date:2/11/2016)... WESTPORT, Conn. , Feb. 11, 2016  AfterPill.com ... decision to recommend alcohol abstinence for all women who ... women in the U.S. each year and raises the ... --> --> According to the ... U.S., 70% of women of child-bearing age, who have ...
Breaking Medicine Technology:
(Date:2/12/2016)... Omaha, NE (PRWEB) , ... February 12, 2016 , ... ... list of the five most searched jobs via the website of healthcare staffing leader ... professionals in travel nurse jobs , travel therapy positions and in ...
(Date:2/12/2016)... Texas (PRWEB) , ... February 12, 2016 , ... Yisrayl ... a revealing article this week that uncovers what he says are the real facts ... stories of the Bible from parents and Sunday school teachers, and Yisrayl says there ...
(Date:2/12/2016)... ... , ... With the exception of restorative dentistry, to date there has been no other option ... by the FDA, there is a now a new protocol in stopping cavity progression; Silver ... and quick to apply. The application is as simple as drying the tooth and ...
(Date:2/11/2016)... ORLEANS (PRWEB) , ... February 11, 2016 , ... “ ... Achieving Satisfaction through a Well Managed Mind” (published by Balboa Press) teaches readers how ... way of being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western ... (AOA) Match Program Tuesday, February 9, taking one of the final steps in ... medical education positions across the country. Of the 103 student-doctors who comprise the ...
Breaking Medicine News(10 mins):